What Analysts Are Saying About CytoSorbents Stock
In the latest quarter, 4 analysts provided ratings for CytoSorbents (NASDAQ:CTSO), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 0 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $7.69, along with a high estimate of $10.00 and a low estimate of $0.75. This current average represents a 0.77% decrease from the previous average price target of $7.75.
Breaking Down Analyst Ratings: A Detailed Examination
In examining recent analyst actions, we gain insights into how financial experts perceive CytoSorbents. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jason Kolbert | D. Boral Capital | Maintains | Buy | $10.00 | $10.00 |
| Jason Kolbert | D. Boral Capital | Maintains | Buy | $10.00 | $10.00 |
| Jason Kolbert | D. Boral Capital | Maintains | Buy | $10.00 | $10.00 |
| Sean Lee | HC Wainwright & Co. | Lowers | Neutral | $0.75 | $1.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CytoSorbents. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of CytoSorbents compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for CytoSorbents's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CytoSorbents's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on CytoSorbents analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About CytoSorbents
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Financial Milestones: CytoSorbents's Journey
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, CytoSorbents showcased positive performance, achieving a revenue growth rate of 10.12% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: CytoSorbents's net margin is impressive, surpassing industry averages. With a net margin of -33.42%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CytoSorbents's ROE stands out, surpassing industry averages. With an impressive ROE of -30.77%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): CytoSorbents's ROA excels beyond industry benchmarks, reaching -6.76%. This signifies efficient management of assets and strong financial health.
Debt Management: CytoSorbents's debt-to-equity ratio stands notably higher than the industry average, reaching 3.01. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
The Basics of Analyst Ratings
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.